Traditional Chinese medicine preparation for treating liver cancer

Abstract

The invention relates to a medical configuration item, in particular to a traditional Chinese medicine preparation for treating liver cancer. The preparation is composed of an effective ingredient and medically acceptable excipients, wherein the effective ingredient is prepared by the following bulk drugs on a mass basis: 5-30% of underleaf pearl, 5-20% of sophora flavescens, 5-30% of rabdosia serra, 4-10% of panax notoginseng, 5-25% of salvia, 4-15% of peach kernel, 4-10% of bupleurum, 5-25% of ligustrum lucidum, 5-25% of yerbadetajo herb, 2-25% of radix pseudostell, and 2-10% of licorice. By combining above 11 drugs, the preparation has heat-clearing and detoxifying, blood-activiating and stasis-dissolving, liver-soothing and depression-resolving, spleen-invigorating and kidney-tonifying efficacy, and furthermore the preparation can inhibit the growth of tumors and achieve the purpose of treating liver cancers.

Description

technical field [0001] The invention relates to medical preparations, in particular to Chinese patent medicines with plants as raw materials. Background technique [0002] Primary liver cancer (PLC, referred to as liver cancer) is one of the most common malignant tumors in clinical practice. It ranks third in cancer-related deaths. my country is a country with a high incidence of liver cancer. Every year, 306,000 people develop the disease, accounting for about 55% of the world's new cases, and about 300,000 people die of liver cancer every year. It is a major disease that seriously threatens the health and life of our people. [0003] The pathogenesis of liver cancer is the result of multiple factors, multiple steps, and multiple gene mutations. The cause of the disease is closely related to post-hepatitis cirrhosis caused by hepatitis B virus (HBV) infection or hepatitis C virus (HCV) infection, and alcoholic cirrhosis caused by long-term alcoholism. [0004] At present...

AI Technical Summary

Problems solved by technology

[0004] At present, in addition to surgical resection, Western medicine mainly uses interventional therapy and chemotherapy in the treatment of liver cancer. However, even with radical resection, there is still a recurrence rate of 60% to 70% within 5 years; , Hepatic function limitation of cirrhosis and other reasons make about 30% of patients with liver cancer who can be surgically resected, while the operability rate of patients with cirrhosis is only 15%-30%

Due to the low selectivity of current chemotherapeutic drugs, while killing tumor cells, they also have a killing effect on normal cells of the body; there is also the risk of inducing secondary tumors and multidrug resistance, these factors severely limit the clinical use of chemotherapeutic drugs

Images